Advanced search
Start date

Development and characterization of delivery systems containing docetaxel for optimization of prostate cancer therapy: imunoliposomes and polymeric nanoparticles


Prostate cancer is the most prevalent type of cancer in men, but its therapy is associated with many effects and limited effectiveness. Docetaxel is one of the first choice antitumor drugs used in conventional therapy for several types of cancer - including prostate - but it presents severe side effects. Pharmaceutical technology has been using important strategies for the purpose of turning cancer therapy more efficient and less aggressive to normal cells, situation where nanostructured release systems stand out. The present study aims to develop and evaluate the efficacy of two different nanostructured release systems containing docetaxel against prostate cancer cell lines. Polymeric nanoparticles and immunoliposomes will be developed and characterized by their physico-chemical and morphological characteristics. The in vitro cytotoxicity will be evaluated by different techniques and in distinct lines of prostate cancer cells, allowing a set of formulations and conclusions on the viability of each one of them. Finally, efficacy studies using xenotransplantation model in immunosuppressed mice will be conducted. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items